

continued...

Horses typically show a gradual reduction in lameness during the first week after treatment. This continues to improve over the ensuing weeks. Please discuss optimal timing of administration of ARTHRAMIDVET with your veterinarian.

Results can be long-lasting (up to 2 years), however, repeat doses are safe and can be given as soon as 4-6 weeks post initial injection. Typically, regular intervals are between 6 to 12 months if clinically indicated or advised.³

Testimonials

ARTHRAMIDVET is a game changer for all equine athletes. It all starts in the synovium with synovitis and capsulitis, before we get to osteoarthritis. I routinely tell my horse owners, "save the synovium, save the joint." – Dr. Dan Carter – Owner of Countryside Veterinary Hospital – Covington, GA

"It's given me another tool in my arsenal to effectively manage all stages of equine osteoarthritis, especially those horses with equine metabolic disease." – Dr. Vern Dryden – Owner of Bur Oak Sports Medicine and Lameness – Lexington, KY

References

1. Christensen, L., Camitz, L., Illigen, K.E., Hansen, M., Sarvaa, R., Conaghan, P.G., Synovial incorporation of polyacrylamide hydrogel after injection into normal and osteoarthritic animal joints. *Osteoarthritis Cartilage*. 2016; 24: 1999-2002.
2. de Clifford L, Lowe J, McKellar C, McGowan C, David F. A Double-Blinded Positive Control Study Comparing the Relative Efficacy of 2.5% Polyacrylamide Hydrogel (PAAG) Against Triamcinolone Acetonide (TA) and Sodium Hyaluronate (HA) in the Management of Middle Carpal Joint Lameness in Racing Thoroughbreds. *Journal Equine Vet Science*, 2022; 107: Available from: <https://doi.org/10.1016/j.jevs.2021.103780>
3. Thibbar, A., Schougaard, H., Camitz, L., Rasmussen, J., Koene, M., Jahn, W., Markussen, B., An international multi-centre prospective study on the efficacy of an intrarticular polyacrylamide hydrogel in horses with osteoarthritis: a 24 month follow up. *Acta Vet Scand*. 2015; 57: 20-27.
4. Traumatic Arthritis and Posttraumatic Osteoarthritis in the Horse. C. Wayne McIlwraith, in *Joint Disease in the Horse* (Second Edition), 2016. The Importance of Synovitis. Synovitis (and capsulitis) is important to the horse because it produces pain, the increased synovial effusion is uncomfortable, it eliminates the normal small negative pressure within the joint (therefore promoting micro-instability), and it produces products that are deleterious to joint health as a whole and articular cartilage in particular. The mediators currently considered to be of significance in equine joint disease include metalloproteinases and aggrecanases, prostaglandins, free radicals, cytokines, IL-1, and possibly TNF α (Figure 3-2). As mentioned previously, human OA was long considered a "wear and tear" disease leading to loss.

Key Points

- Proven efficacy in multiple clinical trials across multiple equine disciplines
- Over 20+ years of research in horses and humans, Contura continues its commitment to ongoing research and development
- Unique and patented 2.5% iPAAG technology for the treatment of joint lameness (including early and late stages of OA)
- Acts as a bio-scaffold, resulting in a decrease in pain and lameness¹
- Non pharmacological action
- Long lasting results and sustained soundness (lame free)³
- Can safely be used to treat multiple joints concurrently in the same animal²

ARTHRAMIDVET®



CONTACT YOUR VETERINARIAN ABOUT USING
ARTHRAMIDVET® FOR YOUR EQUINE ATHLETE

Contura Vet (USA) Inc.
3401 Mallory Lane,
Suite 100 • Franklin, TN 37067
Email: contact@conturavet.com
Call Toll Free: (800) 689-2909

ARTHRAMIDVET®

www.arthramid.com

CVUS-EQ-2307201

ARTHRAMIDVET®

An innovative and long-lasting
joint therapy for all stages of
equine osteoarthritis.



2.5% iPAAG




contura
vet

ARTHRAMIDVET®

What is ARTHRAMIDVET®?

ARTHRAMIDVET® is a unique patented 2.5% injectable polyacrylamide hydrogel (iPAAG). It is administered through intra-articular joint injection to manage arthritic joints in horses. 2.5% iPAAG integrates into the synovium of the joint which results in improved joint function and resolution of lameness.




'Synovitis is the single most important factor that contributes to the pain of OA and lameness.'⁴

The synovial membrane matters

The cells of the synovium are responsible for the production and health of joint fluid, which provides cushioning, reduces friction, and nourishes cartilage. If these cells become damaged, the integrity and quality of the joint fluid are diminished, leading to inflammation within the joint space (**synovitis**). Over time, this inflammation can lead to osteoarthritis (OA), resulting in the pain and lameness you are seeing in your horse..

Percent of Horses Sound 6 Weeks After Treatment




Published in JEVS, Vol 107, Dec 2021; 103780

How does ARTHRAMIDVET work?

ARTHRAMIDVET is injected directly into the joint. Once inside the joint space, it adheres to the synovial membrane and creates a long-term "bio-scaffold" within the synovium. This bio-scaffold supports healthy regeneration of the synovium through the body's normal healing processes. Through its unique patented technology, ARTHRAMIDVET strengthens the affected joint and restores function and freedom of movement, allowing the horse to enjoy a healthy and active life.

Time after administration of ARTHRAMIDVET



Over the next 4-8 weeks ARTHRAMIDVET becomes fully integrated into the synovial membrane, working with the body's natural immune response through ingrowth of new cells, blood vessels, and collagen fibers.

Augmentation of the synovial membrane results in:

- Enhanced, more elastic and flexible joint capsule
- Proliferation of synovial cells, which are responsible for producing synovial joint fluid
- The effect on the synovial membrane and joint capsule along with the sustainability of ArthramidVet within the synovium represent a new treatment therapy for the management of Equine OA

Tnibar A. Intra-articular 2.5% polyacrylamide hydrogel, a new concept in the medication of equine osteoarthritis: A review. J Equine Vet Sci. 2022 Dec;119:104143. doi: 10.1016/j.jevs.2022.104143. Epub 2022 Oct 20. PMID: 36273533.

Is ARTHRAMIDVET right for your horse?

Horses of any age can develop osteoarthritis.

ARTHRAMIDVET can be used in any synovial joint with signs of dysfunction, such as pain, effusion (fluid), reaction to flexion, or visible lameness. Treatment of multiple joints at one time is safe.² Arthritic conditions which are recent (acute) or longer term (chronic) are suitable.

Ideal candidates for ARTHRAMIDVET are those where a veterinary assessment has localized the pain or inflammation to the joint, and arthritis has been confirmed.

The most commonly treated equine joints include coffin, fetlocks, carpus (knees), hocks, and stifles.

Ideally, plan treatment early in the training preparation phase or before maximal workload.

How is ARTHRAMIDVET administered?

This product is for veterinary use only and must be administered via intra-articular injection by a veterinarian.

Your veterinarian will decide the dose required, typically 1-2 ml per joint, depending on the joint size, the severity, and the time since onset of the disease.

How do you manage your horse after treatment with ARTHRAMIDVET?

As with all intra-articular therapies, rest and gradual return to work is recommended. Rest your horse for 48 hours after treatment. Discuss a rehab plan with your veterinarian to maximize the treatment and potentially produce longer lasting results.

A follow-up examination by your veterinarian 4-6 weeks later is advised to assess the response to treatment. In horses with an observed partial response (around 15% of cases), additional treatment may be recommended, or your veterinarian may reassess the original diagnosis.